+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report by Source, by Service (Upstream, Downstream, Fill/Finish), by Product (Biologics), by Region and Segment Forecasts, 2022-2030

  • PDF Icon

    Report

  • 193 Pages
  • April 2022
  • Region: Global
  • Grand View Research
  • ID: 5415424
The global biopharmaceuticals contract manufacturing market size is expected to reach USD 27.3 billion by 2030, growing at a CAGR of 5.2% from 2022 to 2030. Growing biopharmaceutical pipeline and lack of adequate manufacturing capabilities are two key factors that are driving partnership between large molecule manufacturers and Contract Manufacturing Organizations (CMOs). Contract manufacturers are engaged in broadening their service portfolio to meet the companies' demands with respect to regulatory standards and new services. The pandemic has, however, also had some negative knock-on effects as budgets and resources are diverted to “COVID products” at the expense of other biologics projects in development for other therapeutic areas.



The reliance of companies on CMOs for the production of biologics and biosimilars is expected to rise during the forecast period as a consequence of changes adopted by the CMOs. This is evident through growing investment in collaborations of companies with CMOs as well as continuous efforts taken up for expanding the service portfolio. The supply chain of biopharmaceuticals remained robust and was largely unaffected worldwide during the coronavirus outburst. Also, biopharmaceutical contract manufacturers are observing increased demand related to COVID-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the market. For instance, in 2020, AstraZeneca and Oxford Biomedica signed a one-year clinical and commercial supply agreement for the manufacturing of AstraZeneca’s COVID-19 vaccine candidate, AZD1222.

The future growth of the market is highly dependent on the promising opportunities offered by the biopharmaceutical industry, bioprocessing industry, and contract service industry. Expansion of fill-and-finish services and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market. For instance, in 2019, Shanghai HaiHe Biopharma Co. Ltd. raised USD 146.6 million as venture capital for its large cancer drug portfolio, which it shall utilize along with its outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

Biopharmaceuticals Contract Manufacturing Market Report Highlights

  • Mammalian-based biopharmaceutical contract manufacturing captured the largest market share about 58% in 2021 owing to the high penetration of mammalian expression systems for biologics development.
  • Out of all the services offered in this market, process development contributed to the largest share of 33% in 2021, owing to high capital investment, especially in downstream process.
  • Biologics contract manufacturing dominated its counterpart segment owing to higher demand for biologics production. However, the biosimilar segment is growing with a lucrative CAGR of 8.3% due to cost-saving advantages associated with biosimilars development.
  • The presence of an effective regulatory framework for biologics development in the U.S. has resulted in a large share of the North America market of 34.0% in 2021.
  • However, Asia Pacific is expected to emerge as the fastest-growing regional market with a CAGR of 5.8% from 2022 to 2030, owing to developing economies such as India and China incorporating developments to sustain the competition.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Biopharmaceuticals Contract Manufacturing Market

What is the estimated value of the Global Biopharmaceuticals Contract Manufacturing Market?

The Global Biopharmaceuticals Contract Manufacturing Market was estimated to be valued at $18.2 Billion in 2022.

What is the growth rate of the Global Biopharmaceuticals Contract Manufacturing Market?

The growth rate of the Global Biopharmaceuticals Contract Manufacturing Market is 5.2%, with an estimated value of $27.3 Billion by 2030.

What is the forecasted size of the Global Biopharmaceuticals Contract Manufacturing Market?

The Global Biopharmaceuticals Contract Manufacturing Market is estimated to be worth $27.3 Billion by 2030.

Who are the key companies in the Global Biopharmaceuticals Contract Manufacturing Market?

Key companies in the Global Biopharmaceuticals Contract Manufacturing Market include Boehringer Ingelheim GmbH, Lonza, Inno Biologics Sdn Bhd, Rentschler Biotechnologie GmbH, Jrs Pharma, Celonic AG, Agc Biologics, Biomeva GmbH and Financial Performance of Agc.

Table of Contents

Chapter 1 Executive Summary
1.1 Market Snapshot
Chapter 2 Research Methodology
2.1 Information Procurement
2.1.1 Purchased Database
2.1.2 Internal Database
2.2 Data Analysis
2.3 Market Formulation & Validation
2.4 Approaches for Market Estimation
2.4.1 Approach 1: Commodity Flow & Bottom-Up Approach
2.4.2 Approach 2: Top-Down and Parent Market Analysis
Chapter 3 Market Variables, Trends& Scope
3.1 Market Segmentation &Scope
3.1.1 Market driver analysis
3.1.1.1 Rise in investment by CMOs for capacity expansion
3.1.1.2 Commercial success of biopharmaceuticals and consequent increase in demand for biopharmaceuticals
3.1.1.2.1 NoTable growth of biologics
3.1.1.3 Robust biopharmaceuticals pipeline
3.1.1.4 Cost and time-saving benefits offered by contract services
3.1.2 Market restraint analysis
3.1.2.1 Limited outsourcing amongst well-established biopharmaceutical manufacturers
3.2 Opportunity analysis
3.2.1 Expansion of fill-and-finish CMOs
3.2.2 Emergence of single-use bioprocessing equipment & solutions
3.2.3 Funding & investments
3.3 Trend Analysis
3.3.1 Merger & acquisitions in CMO industry
3.3.2 Trading of CMOs at strong EV/EBITDA multiples
3.3.3 Current trends in the biopharmaceutical industry
3.4 Pipeline Analysis
3.4.1 Distribution of products & projects in the development stage by clinical phase
3.4.1.1 Key finding of the analysis:
3.4.2 Pipeline analysis for biosimilar drugs, as of February 2018
3.4.3 Total global biopharmaceutical R&D spending
3.4.4 Number of drugs in a clinical development phase, 2015
3.5 Pricing Analysis for Process Development
3.5.1 Cell line/expression system pricing
3.5.2 Bioreactor cost
3.5.3 Operating and construction cost advantage due to single-use bioprocessing equipment
3.5.4 Bioprocessing operating cost items and ranges
3.5.5 Bioprocessing pricing analysis based on product type
3.5.6 Downstream bioprocessing pricing analysis
3.5.6.1 Cost analyses for buffer purchasing
3.6 Penetration &Growth Prospect Mapping for Contract Manufacturing Service, 2021
3.7 Biopharmaceuticals Contract Manufacturing Market -Swot Analysis, by Factor (Political & Legal, Economic and Technological)
3.8 Industry Analysis - Porter’s
3.9 Customer Relationship Management in Contract Manufacturing
3.9.1 Selection process of CMO
3.9.2 Operations and quality oversight of CMOs
Chapter 4 Biopharmaceuticals Contract Manufacturing Market: Source Estimates & Trend Analysis
4.1 Global Biopharmaceuticals Contract Manufacturing Market: Source Movement Analysis
4.2 Mammalian Source
4.2.1 Global mammalian source market, 2017-2030 (USD Million)
4.3 Non-mammalian Source
4.3.1 Global non-mammalian source market, 2017-2030 (USD Million)
Chapter 5 Biopharmaceuticals Contract Manufacturing Market: Service Estimates & Trend Analysis
5.1 Global Biopharmaceuticals Contract Manufacturing Market: Service Movement Analysis
5.2 Process development
5.2.1 Global process development market, 2017-2030 (USD Million)
5.2.2 Downstream processing
5.2.2.1 Global downstream processing market, 2017-2030 (USD Million)
5.2.3 Upstream processing
5.2.3.1 Global upstream processing market, 2017-2030 (USD Million)
5.3 Fill & finish operations
5.3.1 Global fill & finish operations market, 2017-2030 (USD Million)
5.4 Analytical & QC studies
5.4.1 Global analytical & QC studies market, 2017-2030 (USD Million)
5.5 Packaging
5.5.1 Global contract packaging market, 2017-2030 (USD Million)
Chapter 6 Biopharmaceuticals Contract Manufacturing Market: Product Estimates & Trend Analysis
6.1 Global Biopharmaceuticals Contract Manufacturing Market: Product Movement Analysis
6.2 Biologics
6.2.1 Global biologics market, 2017-2030 (USD Million)
6.2.2 Monoclonal Antibodies
6.2.2.1 Global monoclonal antibodies market, 2017-2030 (USD Million)
6.2.3 Recombinant proteins
6.2.3.1 Global recombinant proteins market, 2017-2030 (USD Million)
6.2.4 Vaccines
6.2.4.1 Global vaccines market, 2017-2030 (USD Million)
6.3 Antisense, RNAi, & molecular therapy
6.3.1.1 Global antisense, RNAi, & molecular therapy market, 2017-2030 (USD Million)
6.3.2 Others
6.3.2.1 Global other product market, 2017-2030 (USD Million)
6.4 Biosimilar
6.4.1 Global biosimilar market, 2017-2030 (USD Million)
Chapter 7 Biopharmaceuticals Contract Manufacturing Market: Regional Estimates & Trend Analysis, by Service, Source, & Product
7.1 Biopharmaceuticals Contract Manufacturing Market Share by Region, 2021 & 2030
7.2 North America
7.2.1 North America biopharmaceuticals contract manufacturing market, 2017-2030 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. biopharmaceuticals contract manufacturing market, by source, 2017-2030 (USD Million)
7.2.2.2 U.S. biopharmaceuticals contract manufacturing market, by service, 2017-2030 (USD Million)
7.2.2.3 U.S. biopharmaceuticals contract manufacturing market, by product, 2017-2030 (USD Million)
7.2.3 Canada
7.2.3.1 Canada biopharmaceuticals contract manufacturing market, by source, 2017-2030 (USD Million)
7.2.3.2 Canada biopharmaceuticals contract manufacturing market, by service, 2017-2030 (USD Million)
7.2.3.3 Canada biopharmaceuticals contract manufacturing market, by product, 2017-2030 (USD Million)
7.3 Europe
7.3.1 Europe biopharmaceuticals contract manufacturing market, 2017-2030 (USD Million)
7.3.2 Germany
7.3.2.1 Germany biopharmaceuticals contract manufacturing market, by source, 2017-2030 (USD Million)
7.3.2.2 Germany biopharmaceuticals contract manufacturing market, by service, 2017-2030 (USD Million)
7.3.2.3 Germany biopharmaceuticals contract manufacturing market, by product, 2017-2030 (USD Million)
7.3.3 France
7.3.3.1 France biopharmaceuticals contract manufacturing market, by source, 2017-2030 (USD Million)
7.3.3.2 France biopharmaceuticals contract manufacturing market, by service, 2017-2030 (USD Million)
7.3.3.3 France biopharmaceuticals contract manufacturing market, by product, 2017-2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific biopharmaceuticals contract manufacturing market, 2017-2030 (USD Million)
7.4.2 China
7.4.2.1 China biopharmaceuticals contract manufacturing market, by source, 2017-2030 (USD Million)
7.4.2.2 China biopharmaceuticals contract manufacturing market, by service, 2017-2030 (USD Million)
7.4.2.3 China biopharmaceuticals contract manufacturing market, by product, 2017-2030 (USD Million)
7.4.3 India
7.4.3.1 India biopharmaceuticals contract manufacturing market, by source, 2017-2030 (USD Million)
7.4.3.2 India biopharmaceuticals contract manufacturing market, by service, 2017-2030 (USD Million)
7.4.3.3 India biopharmaceuticals contract manufacturing market, by product, 2017-2030 (USD Million)
7.5 Latin America
7.5.1 Latin America biopharmaceuticals contract manufacturing market, 2017-2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil biopharmaceuticals contract manufacturing market, by source, 2017-2030 (USD Million)
7.5.2.2 Brazil biopharmaceuticals contract manufacturing market, by service, 2017-2030 (USD Million)
7.5.2.3 Brazil biopharmaceuticals contract manufacturing market, by product, 2017-2030 (USD Million)
7.6 Middle East & Africa (MEA)
7.6.1 Middle East & Africa biopharmaceuticals contract manufacturing market, 2017-2030 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa biopharmaceuticals contract manufacturing market, by source, 2017-2030 (USD Million)
7.6.2.2 South Africa biopharmaceuticals contract manufacturing market, by service, 2017-2030 (USD Million)
7.6.2.3 South Africa biopharmaceuticals contract manufacturing market, by product, 2017-2030 (USD Million)
Chapter 8 Competitive Landscape
8.1 Strategy Framework
8.2 Market Participation Categorization
8.3 Company Profiles
8.3.1 Boehringer Ingelheim GmbH
8.3.1.1 Company overview
8.3.1.2 Financial performance
8.3.1.3 Product benchmarking
8.3.1.4 Strategic initiatives
8.3.2 Lonza
8.3.2.1 Company overview
8.3.2.2 Financial performance
8.3.2.3 Product benchmarking
8.3.2.4 Strategic initiatives
8.3.3 Inno Biologics Sdn Bhd
8.3.3.1 Company overview
8.3.3.2 Financial performance
8.3.3.3 Product benchmarking
8.3.3.4 Strategic initiatives
8.3.4 Rentschler Biotechnologie GmbH
8.3.4.1 Company overview
8.3.4.2 Financial performance
8.3.4.3 Product benchmarking
8.3.4.4 Strategic initiatives
8.3.5 JRS PHARMA
8.3.5.1 Company overview
8.3.5.1.1 CELONIC AG
8.3.5.2 Financial performance
8.3.5.2.1 Financial performance
8.3.5.3 Product benchmarking
8.3.5.4 Strategic initiatives
8.3.6 AGC Biologics
8.3.6.1 Company overview
8.3.6.2 BIOMEVA GmbH
8.3.6.2.1 Company overview
8.3.6.3 CMC Biologics
8.3.6.3.1 Company overview
8.3.6.4 Financial performance of AGC
8.3.6.4.1 Financial performance of BIOMEVA GmbH
8.3.6.4.2 Financial performance of CMC Biologics
8.3.6.5 Product benchmarking
8.3.6.6 Strategic initiatives
8.3.6.6.1 Biomeva GmbH
8.3.6.6.2 CMC Biologics
8.3.7 ProBioGen
8.3.7.1 Company overview
8.3.7.2 Financial performance
8.3.7.3 Product benchmarking
8.3.7.4 Strategic initiatives
8.3.8 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
8.3.8.1 Company overview
8.3.8.2 Financial performance
8.3.8.3 Product benchmarking
8.3.8.4 Strategic initiatives
8.3.9 TOYOBO CO., LTD.
8.3.9.1 Company overview
8.3.9.2 Financial performance
8.3.9.3 Product benchmarking
8.3.9.4 Strategic initiatives
8.3.10 Samsung BioLogics
8.3.10.1 Company overview
8.3.10.2 Financial performance
8.3.10.3 Product benchmarking
8.3.10.4 Strategic initiatives
8.3.11 Thermo Fisher Scientific, Inc.
8.3.11.1 Company Overview
8.3.11.2 Patheon
8.3.11.2.1 Company overview
8.3.11.2.2 DPx
8.3.11.3 Financial Performance of Thermo Fisher Scientific, Inc.
8.3.11.3.1 Financial performance of Patheon
8.3.11.4 Product benchmarking
8.3.11.5 Strategic initiatives
8.3.12 Binex Co., Ltd.
8.3.12.1 Company overview
8.3.12.2 Financial performance
8.3.12.3 Product benchmarking
8.3.13 WuXi Biologics
8.3.13.1 Company overview
8.3.13.2 Financial performance
8.3.13.3 Product benchmarking
8.3.13.4 Strategic initiatives
8.3.14 AbbVie, Inc.
8.3.14.1 Company overview
8.3.14.2 Financial performance
8.3.14.3 Product benchmarking
8.3.14.4 Strategic initiatives

Companies Mentioned

  • Boehringer Ingelheim GmbH
  • Lonza
  • Inno Biologics Sdn Bhd
  • Rentschler Biotechnologie GmbH
  • Jrs Pharma
  • Celonic AG
  • Agc Biologics
  • Biomeva GmbH
  • Cmc Biologics
  • Financial Performance of Agc
  • Probiogen
  • Fujifilm Diosynth Biotechnologies U.S.A. Inc.
  • Toyobo Co. Ltd.
  • Samsung Biologics
  • Thermo Fisher Scientific, Inc.
  • Binex Co. Ltd.
  • Wuxi Biologics
  • Abbvie, Inc.

Methodology

Loading
LOADING...